Structural Features of LIM Kinase That Control Effects on the Actin Cytoskeleton*

David C. EdwardsDagger and Gordon N. Gill§

From the Departments of Dagger  Chemistry and § Medicine, University of California San Diego, School of Medicine, La Jolla, California 92093

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

LIM kinase phosphorylates and inactivates the actin binding/depolymerizing factor cofilin and induces actin cytoskeletal changes. Several unique structural features within LIM kinase were investigated for their roles in regulation of LIM kinase activity. Disruption of the second LIM domain or the PDZ domain or deletion of the entire amino terminus increased activity in vivo measured as increasing aggregation of the actin cytoskeleton. A kinase-deleted alternate splice product was identified and characterized. This alternate splice product and a kinase inactive mutant inhibited LIM kinase in vivo, indicating that the amino terminus suppresses activity of the kinase domain. Mutation of threonine 508 in the activation loop to valine abolished activity whereas replacement with 2 glutamic acid residues resulted in a fully active enzyme. Dephosphorylation of LIM kinase inhibited cofilin phosphorylation. Mutation of the basic insert in the activation loop inhibited activity in vivo, but not in vitro. These results indicate phosphorylation is an essential regulatory feature of LIM kinase and indicate that threonine 508 and the adjacent basic insert sequences of the activation loop are required for this process. A combination of structural features are thus involved in receiving upstream signals that regulate LIM kinase-induced actin cytoskeletal reorganization.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Many protein kinases contain modular domains that regulate catalytic activity, direct localization to specific compartments of the cell, and dictate interactions with other components of signal transduction complexes (1). There are 2 identified LIM kinase family members that each contain 2 amino-terminal LIM domains, a central PDZ domain, and a carboxyl-terminal kinase domain with predominant serine/threonine kinase activity (2-4). During mouse development LIM kinase is expressed early in neuroectoderm, cardiac mesoderm, and gut endoderm and later predominantly in brain (5-7). In developing human tissues LIM kinase is also found predominantly in brain where hemizygous deletion of the 7q 11.23 region containing LIM kinase is implicated in the visuospatial constructive cognition defect in Williams syndrome (8).

Major unanswered questions have been how LIM kinase functions and how it is regulated. Cofilin has been identified as a functionally important substrate for LIM kinase and evidence has been provided that LIM kinase regulates actin dynamics by phosphorylation and inactivation of cofilin (9, 10). Actin-depolymerizing factor/cofilamentous protein (cofilin) which binds to both F-actin and actin monomers (11-13) is essential for depolymerization of actin filaments (14). It binds more tightly to ADP-actin than to ATP-actin and enhances the off rate of actin monomers at the pointed end of fibers (15). At pH 8.0 and above, cofilin depolymerizes actin stoichiometrically (16, 17). This is essential to actin dynamics necessary for cell motility, cytokinesis, and other cell processes (18-20). Cofilin exists in both a phospho and dephospho form, with phosphorylation inhibiting the actin filament severing activity (21, 22). Ser3 is the principal inhibitory phosphorylation site in cofilin and previous studies indicated it was a poor substrate for known kinases including protein kinase C, cyclic AMP-dependent protein kinase, myosin light chain kinase, and CaM kinase II (21). By using dominant negative forms of LIM kinase and constitutively active forms of Rac, Arber et al. (9) and Yang et al. (10) deduced that LIM kinase is the downstream effector of Rac-dependent actin cytoskeleton changes. Because activated Rac did not interact directly with LIM kinase, Rac regulation of LIM kinase activity must involve intermediate biochemical steps.

The kinase domain of LIM kinase contains significant sequence variations compared with other serine/threonine kinases in the ATP-binding site (subdomain VIB) (23), the substrate-binding region of subdomain VIII and in the presence of an 11-amino acid basic insert in the activation loop between subdomains VII and VIII (2-4). Although the sequence of the LIM domains of LIM kinase more closely resemble those of nuclear LIM homeodomain and LIM-only proteins than those of cytoplasmic proteins (24), the LIM domains of LIM kinase do not recognize the nuclear LIM interactor that binds nuclear LIM domains with high affinity (25). The predominant cytoplasmic localization of LIM kinase (2, 4) and its ability to bind actin (10) indicate that it, like many other extranuclear LIM domain containing proteins, functionally associates with the cytoskeleton. Zyxin, cysteine-rich protein and paxillin are localized along actin filament bundles and at adhesion plaques (26, 27). The actin LIM protein is localized to the cytoskeleton via its PDZ domain (28) while cysteine-rich protein 1 binds to alpha -actinin via its first LIM domain (29). Deletion of muscle LIM protein (cysteine-rich protein 3 or muscle LIM protein), which localizes to actin filaments via LIM domains, results in disruption of cardiomyocyte architecture and dilated cardiomyopathy (30). Some PDZ domains that bind to the consensus Ser/Thr-X-Val/Leu/Ile at the carboxyl terminus of target proteins (31) also bind to the cytoskeleton via interaction with alpha -actinin-2 (28). Other PDZ domain containing proteins also bind to actin via F-actin-binding domains (32, 33). LIM kinase thus contains structural features of cytoskeletal regulatory proteins and kinase activity specific for cofilin.

To determine features that regulate LIM kinase we have measured the activity of LIM kinase using transient transfection in COS-7 cells. An in vivo assay of the biochemical activity of LIM kinase is based upon the morphological extent of actin cable dissolution and subsequent aggregation that results from inactivation of cofilin. Mutations were introduced into the LIM, PDZ, and kinase domains to assess their contributions to the activity of LIM kinase that causes actin accumulation in large uncleaved aggregates that were visualized by fluorescently labeled phalloidin binding. Additionally, co-expression of an amino-terminal fragment that corresponds to a naturally occurring splice variant with holo LIM kinase inhibited actin aggregation. These studies indicate that the amino-terminal fragment that contains the LIM and PDZ domains inhibits the catalytic activity of the kinase domain. These studies also indicate that a threonine residue in the catalytic loop, which is a major phosphorylation site in other kinases, is necessary for catalytic activity and that the basic insert in the activation loop contributes to biological activity. The unique structural features of LIM kinase located both outside and within the kinase domain thus control enzyme activity, subcellular distribution, and substrate recognition necessary for regulation of actin dynamics.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- COS-7 and HEK 293 cells were obtained from the American Type Tissue Culture Collection, (Manassas, VA). Six-well tissue culture plates and preferred glass coverslips were from Fisher Scientific (Pittsburgh, PA) and cell culture media and serum were purchased from FMC (Rockland, DE). Oligonucleotides used for mutagenesis were made by Operon Technologies (Alameda, CA) and molecular biology enzymes were purchased from New England Biolabs (Beverly, MA). All polymerase chain reaction (PCR)1 products were amplified with Pfu polymerase. Cofilin was a kind gift from Laurent Blanchoin and Tom Pollard (Salk Institute, La Jolla, CA).

RT-PCR Cloning and Library Screening-- RNA from A431 cells was harvested using Tri-Reagent (Molecular Research Center Inc., Cincinnati, OH) and reverse transcriptase polymerase chain reactions (RT-PCR) were carried out using the Superscript cDNA Cloning Kit (Stratagene, La Jolla, CA) with random hexamers as the primers for the cDNA synthesis reaction. LIM kinase and dLIM kinase were amplified from the resulting cDNA library using primers with the sequences, 5'-GTCACTAAGCTTCATGAGGTTGACGCTACTTTGT-3' for the 5' end, and 5'-GTCACTAAGCTTCAGTCGGGGACCTCAGGGTGGGCAGG-3' for the 3' end. The PCR products were amplified with Pfu polymerase, digested with HindIII, and ligated into the HindIII sites in the cloning vector, pBlueScriptII-KS (Stratagene). The sequence of the full-length LIM kinase and dLIM kinase were verified by sequencing using Sequenase 2.0 (Amersham, Willinghamshire, United Kingdom).

To determine the expression pattern of the dLIM kinase splice variant, 18 libraries were screened using RT-PCR. Four libraries were obtained: human fetal brain (a kind gift from Dimitri Krainc and R. Brent, Harvard, Boston, MA), HeLa and SK-N-MC(CLONTECH, Palo Alto, CA), human placenta and A431 (Stratagene), and 14 libraries were made from cultured cells using the Superscript cDNA Cloning Kit. Oligonucleotide primers (5' primer 5'-CCCCTGAGCTCTCCGGCTTATACTC-3' and 3' primer 5'-CCTCCTTGAGGAACGTCCTCTGGGT-3') were made that would amplify the region in LIM kinase that contains the deletion. PCR amplification of the region around the alternate splice site would produce a 270-nucleotide (nt) fragment, while amplification of the identical region in full-length LIM kinase would produce a 331-nt fragment. PCR reactions were then run on a 1.5% agarose gel and stained with ethidium bromide.

Site-directed Mutagenesis-- All LIM kinase mutations were made by overlap extension (34, 35), except for the G177E/L178A and T508EE, which replaces Thr508 with 2 Glu residues which were made using the Quickchange mutagenesis kit (Stratagene). A schematic representation of mutant LIM kinases is shown in Fig. 1. Kd1 and Kd3 constructs were made using 5' primers 5'-GACTCATCGAGTCGGACCTCATCCACGGGGAGGTGCTG-3' and 5'-GATCCTCGAGCCGGGCGCTGGCTCACTGGGCTCCCCG-3', respectively, and the 3' primer 5'-GCGTCTAGATCAGTCGGGGACCTC-3'. The constructs were amplified by PCR and ligated into the XhoI and NotI sites of pcDNA-3M, a derivative of pcDNA-3 which contains a luciferase start codon and a hemaglutinin epitope tag (HA-tag) (36). Translation is initiated from the luciferase start codon and places an in-frame HA-tag at the amino terminus of the constructs. All mutations were verified by sequencing.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 1.   Mutations in LIM kinase. The indicated mutations in LIM kinase were prepared and inserted into the pcDNA 3 expression vector as described under "Experimental Procedures." Point mutations are in italics with letters corresponding to the one-letter amino acid code. The black box in dLIM kinase represents 12 amino acids not present in wild-type LIM kinase. The black bar within the kinase domain represents the 11-amino acid insertion.

Cell Lines and Culture Conditions-- 293 transformed human kidney and COS-7 green monkey kidney cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum in a humidified 8% CO2 atmosphere at 37 °C. All constructs were cloned into pcDNA-3 (Invitrogen, Carlsbad, CA) except Kd1 and Kd3, which were cloned into pcDNA-3M. DNAs were transfected into COS-7 and 293 cells using calcium phosphate-mediated transfection (37).

Production of Polyclonal Antibodies-- A peptide with the sequence KETYRRGESGLPAHPEVPD corresponding to the carboxyl-terminal 18 residues and a peptide that corresponds to residues 255-271, KEHDPHDTLGHGLGPETS, of human LIM kinase were conjugated to keyhole lympet hemocyanin using gluteraldehyde (38). An amino-terminal lysine was included on each peptide to facilitate coupling. The peptide conjugates were used to immunize rabbits or chickens by Lampire Laboratories (Ottsville, PA). Immunoprecipitations were done using the rabbit antibody 5079 directed against the carboxyl-terminal peptide except those involving dLIM kinase where antibody 5078, directed against the internal peptide, was used. Western blotting was done with the chicken antibody 625 directed to the internal peptide. The Kd3 construct was detected using an anti-HA monoclonal antibody (Berkeley Antibody Co., Berkeley, CA).

Immunocytochemistry-- Cells used for immunocytochemistry were plated onto preferred glass coverslips and harvested 60 h after transfection. Cells were fixed with a 4% paraformaldehyde in 1 × phosphate-buffered saline for 25 min at room temperature. To determine LIM kinase expression, cells were incubated 2-3 h with a 1:1,250 dilution of anti-LIM kinase rabbit antibody 5079 in buffer containing 0.1% Triton X-100, 0.024% saponin, and 2% bovine serum albumin. To visualize LIM kinase and to stain for actin filaments, cells were incubated for 2 h in buffer containing goat anti-rabbit Texas Red-conjugated secondary antibody and Oregon Green 488-labeled phalloidin (Molecular Probes, Eugene, OR). Cells were then equilibrated and mounted with Slow Fade mounting media. Pictures were taken with a Zeiss Axiophot microscope with an attached Hamamatsu color chilled CCD camera using × 40 and 60 objectives.

Immunoprecipitation and Kinase Assays-- Transiently transfected 293 cells were grown for 72 h and harvested by washing cells off the plate with phosphate-buffered saline and resuspending in lysis buffer (50 mM Tris-HCl, pH 8.0, 10 mM NaCl, 3% glycerol, 2% Triton X-100, 50 µM benzamidine, 2 µM aprotinin, 2 µM leupeptin, 1 mM phenymethlysulfonyl fluoride, 10 µg/ml pepstatin A, 10 µg/ml phenalthroline) and incubated on ice for 30 min. Cleared lysate was presorbed with preimmune serum and protein A-Sepharose. LIM kinase was then immunoprecipitated using the 5079 anti-LIM kinase antibody and protein A-Sepharose and washed 4 times with lysis buffer. Immunoprecipitates for kinase assays were washed and resuspended in kinase assay buffer (50 mM HEPES, pH 7.4, 150 mM NaCl, 3% glycerol). An aliquot of immunoprecipitated LIM kinase was resuspended in SDS loading buffer and protein estimated by Western blotting using antibody 625 or anti-HA antibody. Protein was detected with goat anti-chicken or anti-mouse secondary antibody conjugated to horseradish peroxidase and visualized with chemiluminescence.

Protein A-Sepharose beads containing immunoprecipitated LIM kinase were resuspended in kinase reaction buffer and incubated for 150 min at 30 °C in kinase reaction buffer with 5 µM ATP and 10 µCi of [gamma -32P]ATP (4500 Ci/mmol), 2 mM MnCl2, and 5 mM MgCl2 with 25 µM cofilin. Reactions were stopped by addition of SDS sample buffer and loading on a 14% SDS-polyacrylamide gel electrophoresis. Gels were dried and exposed to X-Omat AR film (Kodak, Rochester, NY) for 1 h at room temperature with an intensifying screen. Films were scanned with a Molecular Dynamics Personal Densitometer SI and analysis was done using Image Quart Vd 1.1 (Molecular Dynamics). Phosphatase treatment of immunoprecipitated LIM kinase was carried out at 30 °C for 25 min with and without calf intestinal alkaline phosphatase (CIP) (New England Biolabs), in kinase reaction buffer. CIP-treated and mock treated LIM kinase was washed 4 times in kinase reaction buffer and kinase reactions were run as described.

Solution assays contained 200 µM [gamma -32P]ATP (specific activity 0.5 µCi/nmol) varying amounts of cofilin, 2 mM MnCl2, 5 mM MgCl2, 50 mM HEPES (pH 7.4), 150 mM NaCl, and various forms of LIM kinase expressed by transient transfection of HEK 293 cells. Reactions were incubated for the indicated times at 30 °C and terminated by spotting an aliquot onto Whatman 3MM filter disks that were placed in cold 10% trichloroacetic acid. Fillers were sequentially washed in cold/heated/cold 5% trichloroacetic acid, dried in 70% ethanol, and counted. Background values using untransfected HEK 293 cell lysates were subtracted and kinase activity was adjusted for LIM kinase expression quantitated by chemiluminescence imaging using Molecular Dynamics (Bio-Rad) hardware and software. SDS-polyacrylamide gel electrophoresis analysis indicated that >90% of radioactivity incorporated was into cofilin and that cofilin phorphorylation was not detected using untransfected lysates. Triplicate data points are shown for assays that were repeated.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Effects of LIM Kinase on the Actin Cytoskeleton-- To investigate the functional consequences of mutations in LIM kinase, an in vivo assay was developed based on the effects of transiently transfected LIM kinase on the actin cytoskeleton in COS-7 cells. Expression of LIM kinase was assessed using a rabbit polyclonal anti-peptide antibody directed to the carboxyl terminus and effects on the actin cytoskeleton were assessed using fluorescently labeled phalloidin. Fig. 2 shows the range of changes observed in the actin cytoskeleton; protein expression levels were based on the intensity of immunfluorescence and were qualitatively proportional to the extent of changes in the actin cytoskeleton indicated in the panels on the right. At low levels of LIM kinase expression there was a decrease in the extent of actin cables visualized and enhanced membrane staining compared with neighboring untransfected cells (Fig. 2, A and B). Intermediate levels of LIM kinase resulted in loss of the cable-like stress fibers and the appearance of multiple irregular lattice-like actin filaments (Fig. 2, C and D). Higher levels of LIM kinase expression resulted in accumulation of large masses of actin near the cell periphery and diffuse cytoplasmic staining (Fig. 2, E and F). The highest levels of LIM kinase expression resulted in multiple discrete masses of actin (Fig. 2, G and H). The extent of changes in the actin cytoskeleton were scored using a 1+ to 4+ scale. The distribution of these actin cytoskeletal phenotypes in the population of cells expressing LIM kinase are shown in Fig. 4. As reported (2, 4), LIM kinase was expressed in the cytoplasm; at high levels of aggregation the enzyme colocalized with the masses of actin. With extensive disruption of the actin cytoskeleton, multiple nuclei were often observed, consistent with resultant defects in nuclear division.


View larger version (78K):
[in this window]
[in a new window]
 
Fig. 2.   LIM kinase induces an actin aggregation phenotype that is dependent on kinase activity. COS-7 cells were transfected with 1 µg of either WT LIM kinase (A-H) or mutant kinase-inactive LIM kinase D460N (I-J). Cells were transfected, harvested, and stained with anti-LIM kinase antibodies (A, C, E, G, and I) or phalloidin (B, D, F, H, and J). The extent of changes in the actin cytoskeleton are indicated by the scale on the right and the intensity of LIM kinase staining is indicated on the left. The scale bar equals 20 µm, for all figures. The same magnification was used in panels A, B, G-J, and in panels C-F.

A mutation of the predicted catalytic base that changes Asp to Asn (D460N) is reported to abolish LIM kinase activity (6). Even high levels of expression of a D460N mutant LIM kinase gave no change in the actin cytoskeleton compared with untransfected cells (Fig. 2, I and J). In vitro kinase assays confirmed that D460N LIM kinase was devoid of catalytic activity (see Fig. 10). The changes in the actin cytoskeleton were thus dependent on the kinase activity of LIM kinase.

Effect of Mutations of the LIM and PDZ Domains on LIM Kinase-induced Changes in the Actin Cytoskeleton-- To assess the role of the LIM and PDZ domains on LIM kinase function, mutations were introduced which were designed to disrupt each of these domains. The structure of LIM domains is dependent on two Zn2+ atoms that are coordinated tetrahedrally in amino- and carboxyl-terminal liganding modules (39). Metal binding is essential for protein structure and renaturation studies indicate that binding is sequential (40). The first conserved Cys residue of each LIM domain of LIM kinase was mutated to Ser to disrupt metal coordination and LIM domain structure (C25S for the first (LIM1) and C84S for the second (LIM2) LIM domain). Mutations in the PDZ domain were based on the crystal structure of the third PDZ domain of PSD-95 complexed to the carboxyl terminus of the potassium channel (41). The signature sequence Gly-Leu-Gly-Phe that constitutes the protein binding loop of PDZ domains is 177Gly-Leu-Ser-Val in LIM kinase. To disrupt target binding, the LIM kinase PDZ domain 177Gly-Leu was mutated to Glu-Ala (G177E/L178A). These mutations are predicted to disrupt both alignment of backbone interactions and the hydrophobic pocket necessary for protein binding (41). Mutation of the corresponding residues in the PDZ domain of Enigma, which also contains a variant sequence at this position, abolished target recognition.2

As shown in Fig. 3, A and B, mutation of LIM1 did not affect the ability of LIM kinase to induce actin aggregation. Aggregates of actin were observed comparable to those observed with similar levels of WT LIM kinase (see Fig. 2D). Mutation of LIM2 and the PDZ domain increased the ability of LIM kinase to induce actin aggregation (Fig. 3, C-F). At low levels of G177E/L178A LIM kinase expression, phenotypic changes scored as 3+ to 4+ were seen whereas comparable levels of holo LIM kinase expression gave actin cytoskeleton changes scored as 1+ to 2+. As shown in the left panels, mutations in the LIM and PDZ domains did not affect subcellular localization as these mutant LIM kinases remained outside the nucleus. These data indicate that LIM and PDZ domains are not necessary for biological responses to LIM kinase-induced actin aggregation; however, increased activity upon mutational inactivation of the LIM2 and PDZ domains suggests these suppress LIM kinase activity in the holoenzyme structure.


View larger version (85K):
[in this window]
[in a new window]
 
Fig. 3.   The second LIM domain and the PDZ domain negatively regulate the activity of LIM kinase. COS-7 cells were transfected with 1 µg of either LIM kinase C25S (A and B), LIM kinase C84S (C and D), or LIM kinase G177E/L178A (E and F). Cells were stained for LIM kinase (left panels) and actin (right panels), and graded on expression level (left) and actin aggregation (right).

Although transfection of various LIM kinase mutants resulted in equivalent average protein expression per dish (see Fig. 11), expression in individual cells within the population varied as shown in Fig. 2. To assess the relative intrinsic activities of each form of the LIM kinase, the distribution of induced changes in the actin cytoskeleton in a population of cells expressing each mutant were scored and presented as described by Arber and co-workers (9). Fig. 4 shows that actin cytoskeletal changes induced by WT-LIM kinase in COS-7 cells were primarily those indicated by 3+ and 2+ qualitative scores in Fig. 2. Mutational inactivation of LIM2 and the PDZ domain shifted the distribution toward the more severe actin aggregation phenotype indicated as 4+ in Fig. 2H whereas the D460N LIM kinase had little effect on the actin cytoskeleton relative to mock transfected cells.


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 4.   Distribution of actin cytoskeletal phenotypes in cells expressing various LIM kinase mutants. COS-7 cells were transfected with the indicated LIM kinase mutants and stained for LIM kinase and actin. Transfected cells were identified and the actin phenotype scored in 100 cells without knowledge of the form of LIM kinase. , 1+; , 2+; , 3+; black-square, 4+, as defined in the legend to Fig. 2.

Expression of the Kinase Domain of LIM Kinase Is Sufficient to Induce Actin Aggregation-- The observation that disruption of the PDZ domain and the second LIM domain enhanced the in vivo activity of LIM kinase suggested that the kinase domain was sufficient to induce changes in the actin cytoskeleton. Two kinase constructs containing the kinase domain of LIM kinase were made and expressed in COS-7 cells (Fig. 1). Kd1 was composed of the conserved catalytic core of the kinase domain from the glycine-rich loop to the end of LIM kinase (residues 346-647). This construct, which includes all of the conserved residues in the catalytic core, does not include the alpha A helix, which runs down the back of the large and small lobes of cAMP-dependent protein kinase and is important for stability and catalytic activity of that enzyme (42). The second construct, Kd3, which is composed of the entire kinase domain, included the alpha A helix (residues 302-647). This construct corresponds to a naturally occurring splice variant of LIM kinase that is found in testis (43). Even high levels of expression of Kd1 failed to induce changes in the actin cytoskeleton (Fig. 5, A and B). The punctate perinuclear staining suggested that Kd1 may not be folded and processed normally. In contrast, Kd3 was extremely active, inducing a strong aggregation phenotype (Fig. 5, C and D; Fig. 4). The complete kinase domain with the alpha A helix is thus required for biological effects on the actin cytoskeleton. The enhanced activity of Kd3 supports the idea that the amino terminus of LIM kinase suppresses activity of the holenzyme.


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 5.   The kinase domain-only construct Kd3 has high actin aggregating activity. COS-7 cells were transfected with 1 µg of either Kd1 (A and B) or Kd3 (C and D) and stained for LIM kinase (left panels) and actin (right panels) as described under "Experimental Procedures." Expression and aggregation were graded as indicated.

A Splice Variant of LIM Kinase Results in a Kinase-deleted Form-- During cloning of the full-length LIM kinase transcript from an A431 cell cDNA library, a splice variant was found that was identical to the LIM kinase sequence with the exception of a 61-base pair deletion upstream of the region coding for the kinase domain. The deletion, from nt 977 to 1037 in the cDNA relative to the start codon (Fig. 6A), is similar in size to, but differs from, the deletion in the kinase core of LIM kinase reported previously (2). Analysis of the genomic sequence (8) showed that the deletion was the result of differential splicing at the 3' end of intron 7 which joins with the middle of exon 8 at nt 23116 instead of at the 5' end of exon 8, at nt 23055 as occurs with full-length LIM kinase (Fig. 6B). The deletion, located in the sequence between the PDZ domain and the kinase domain, causes a frameshift at amino acid 294 adding 12 amino acids not found in the full-length protein and resulting in a premature truncation at amino acid 305 (Fig. 6C). This truncation deletes the entire kinase domain, resulting in a catalytically inactive protein, termed deleted LIM kinase (dLIM kinase). To determine if the amino-terminal splice variant dLIM kinase was found elsewhere, 18 cDNA libraries, either commercially available or made from cultured cells, were screened using RT-PCR and primers that would allow discrimination between dLIM kinase and LIM kinase. Fig. 6D shows that full-length LIM kinase was found in all samples analyzed (upper band), while dLIM kinase was found in 9 of the 18 analyzed (lower band). In vitro transcription/translation reactions showed that dLIM kinase encoded a 32-kDa protein (data not shown). The truncated protein failed to induce actin bundling in COS-7 cells, and was expressed primarily in the cytoplasm with accumulation in the perinuclear region (Fig. 6E).


View larger version (51K):
[in this window]
[in a new window]
 
Fig. 6.   A splice variant of LIM kinase results in deletion of the kinase domain. A, sequence of the splice junction of the variant dLIM kinase. The deleted sequence is underlined and the intron branch site is double underlined. 32 nt not included are indicated by dots. B, schematic of the intron and exon splicing of the full-length and dLIM kinase constructs. While holo LIM kinase joins the 3' end of exon 7 to the 5' end of exon 8, dLIM kinase joins it to the middle of exon 8. C, sequence of the carboxyl terminus of the splice variant that terminates at Val293 of LIM kinase. Twelve residues added prior to the stop codon are underlined. D, comparative expression of wild-type and variant LIM kinase in various tissues and cell lines as determined by RT-PCR. The full-length LIM kinase PCR product is 331 nt whereas the dLIM kinase PCR product is 270 nt. All cell lines were of human origin except for B82 and CV-1. Fetal brain library was made by Dimitri Krainc (DK). Libraries purchased from Stratagene(ST), CLONTECH(CL) are indicated, except SK-N-MC (lane 5) which was also from CLONTECH. E, immunochemical detection of the splice variant dLIM kinase expressed in COS-7 cells using the internal peptide antibody 5078 (left panel) and lack of effect on the actin cytoskeleton as determined by phalloidin staining (right panel). The sequence data are available from GenBank under accession number AF134379.

The Kinase-inactive D460N LIM Kinase and the dLIM Kinase Splice Variant Inhibit LIM Kinase Activity-- The effect of the kinase-inactive D460N mutant on wild type LIM kinase activity was investigated by co-transfecting expression constructs for both proteins into COS-7 cells. As shown in Fig. 7, A and B, D460N LIM kinase significantly blocked the aggregation of actin induced by wild-type LIM kinase. The inhibitory effects of D460N LIM kinase on the actin phenotypes induced by WT LIM kinase are evident in the distributions shown in Fig. 4. Although some effects of LIM kinase on the actin cytoskeleton persisted, the D460N mutant largely inhibited the biological effects not only of wild-type LIM kinase, but also of LIM kinase containing mutations in LIM1 (C25S), LIM2 (C84S), and the PDZ domain (G177E/L178A) (data not shown).


View larger version (66K):
[in this window]
[in a new window]
 
Fig. 7.   The kinase inactive mutant D460N and the dLIM kinase splice variant act in a dominant interfering manner. COS-7 cells were transfected with 1 µg of each DNA coding for LIM kinase D460N (A, B, G, and H), wild-type LIM kinase (A-F), Kd3 (G-L), Kd1 (C, D, I, and J), and dLIMK (E, F, K, and L) except for panels G and H which were transfected with 4 µg of D460N LIM kinase. Cells were stained for LIM kinase with the 5079 antibody, to detect changes in bundling activity (left panels) and actin (right panels). In panel K dLIM kinase was detected with 5078 internal peptide antibody and Kd3 with the carboxyl-terminal 5079 antibody.

Hiraoka and co-workers (44) reported that when HA-tagged LIM kinase 1 and untagged wild-type protein were coexpressed in COS cells, the two co-immunoprecipitated. Use of GST fusions of fragments of LIM kinase indicated that the self-association of LIM kinase involved interaction of the amino terminus with the carboxyl terminus. The inhibitory effect of D460N on wild-type LIM kinase activity in vivo is compatible with the dominant negative effect being due to the postulated dimerization of the two proteins. Because D460N LIM kinase inhibited the function of LIM kinase that contained mutations in the LIM and PDZ domains it was uncertain which regions were responsible for inhibition. To address this question, we coexpressed the amino-terminal splice variant that lacks the kinase domain and the inactive kinase fragment Kd1, with both wild type LIM kinase and the active kinase fragment Kd3. dLIM kinase inhibited the actin aggregating effects of LIM kinase whereas the inactive kinase fragment Kd1 did not (Fig. 7, C-F). Moreover, dLIM kinase inhibited the activity of the Kd3 kinase domain-only construct whereas Kd1 was without effect (Fig. 7, I-L). In contrast the kinase inactive D460N LIM kinase which inhibited holo LIM kinase did not inhibit Kd3 (Fig. 7, G and H).

The finding that the amino-terminal splice variant dLIM kinase inhibited the activity of Kd3 domain provides functional support for the model of Hiraoka et al. (44) in which LIM kinase monomers self-associates in an antiparallel fashion. The present data indicates that it is the amino terminus which suppresses the kinase activity of the dimeric enzyme. While Hiraoka and co-workers (44) found the LIM domains to be necessary for self-association, the present data indicate that mutation of either LIM domain alone does not abolish interaction as assessed by in vivo activity. An amino-terminal fragment consisting of the 2 LIM domains alone also inhibited LIM kinase activity (data not shown), suggesting that both LIM domains function in this manner. The failure of D460N LIM kinase to inhibit Kd3 suggests that self-association of holoenzyme monomers in which both partners contribute amino- and carboxyl-terminal interaction domains is stronger than association of fragments.

Mutations in the Activation Loop of the Catalytic Core Affect LIM Kinase Activity-- Kinases are regulated by both modular domains and phosphorylation (1, 45). Phosphorylation of a conserved Thr residue in the activation or T loop of several kinases including cAMP-dependent protein kinase, cyclin-dependent kinase 2, and MAP kinase enhances catalytic efficiency (46, 47). MAP kinase is also phosphorylated on Tyr in the sequence Thr-Glu-Tyr in the activation loop and phosphorylation of both sites is required for maximal activity (48, 49). The analogous activation loop Thr residue in LIM kinase, Thr508, is adjacent to a Tyr residue, Tyr507. Proschel et al. (6) reported that a GST kinase domain LIM kinase fusion protein exhibited in vitro autophosphorylation on Ser and Tyr residues with only trace amounts of phosphate on Thr.

To evaluate the requirement for Thr508 and Tyr507 as potential regulatory phosphorylation sites in LIM kinase, Thr508 was mutated to Val (T508V) and Glu (T508E) and Tyr507 was mutated to Phe (Y507F) and activities were assayed. T508V abolished the ability of LIM kinase to induce changes in the actin cytoskeleton in vivo (Figs. 4 and 8, A and B). This loss of enzyme activity suggests that phosphorylation of Thr508 in the activation loop is essential for enzymatic activity. The T508V LIM kinase also interfered with the actin cytoskeleton changes induced by WT LIM kinase (Fig. 4). Changing Thr508 to Glu, which is reported to constitutively activate protein kinase C by mimicking a phosphorylated Thr (50) also resulted in an enzyme that did not exhibit LIM kinase activity as assessed by changes in the actin cytoskeleton (Figs. 4 and 8, C and D).


View larger version (86K):
[in this window]
[in a new window]
 
Fig. 8.   Thr508 is necessary for LIM kinase effects on the actin cytoskeleton. COS-7 cells were transfected with 1 µg of T508V LIM kinase (A and B), T508E LIM kinase (C and D), or Y507F LIM kinase (E and F). Cells were stained for LIM kinase (left panels) and actin (right panels).

To further investigate the potential effects of phosphorylation of Thr508, this residue was mutated in the highly active kinase-only construct Kd3. While Kd3 induced severe actin aggregation (Fig. 9, panels A and B), substitution of Glu for Thr at residue 508 failed to induce actin aggregation in COS-7 cells (Fig. 9, panels C and D), comparable to lack of effects of the kinase inactive Kd3-D46ON mutant (Fig. 9, panels G and H). In contrast, substitution of 2 Glu residues whose charge may more closely resemble a phosphate on Thr (Kd3-T508EE) resulted in full activity comparable to that of Kd3 (Figs. 4 and 9, E and F). These findings resemble studies of Mek1 where substitution of an Asp or Glu residue for 1 serine phosphorylation site partially activated the enzyme and substitution of 2 acidic residues for both serine phosphorylation sites resulted in a fully active enzyme (51). Together, these results suggest that phosphorylation of Thr508 is required for LIM kinase activity. In contrast changing T507F did not reduce LIM kinase activity on the actin cytoskeleton (Fig. 8, panel E). Thus, Thr508 is likely an essential phosphorylation site in LIM kinase whereas Tyr507 is not. The failure to autophosphorylate on Thr in vitro (6) and the lack of kinase activity of bacterially expressed Kd3 (data not shown) suggest Thr508 is phosphorylated in trans by a distinct kinase.


View larger version (82K):
[in this window]
[in a new window]
 
Fig. 9.   Two glutamic acid residues in the activation loop activate LIM kinase. COS-7 cells were transfected with Kd3 (A and B), Kd3 containing a single Glu replacement of Thr (T508E) (C and D), Kd3 containing 2 Glu residues in this area (T508EE) (E and F) or the kinase-inactive mutation D460N in Kd3 (G and H). Cells were stained for LIM kinase (left panels) and actin (right panels).

The activation loop located between subdomains VII and VIII in the catalytic core has been shown to influence substrate recognition in MAPK (52). Both LIM kinases 1 and 2 contain a unique highly basic 11 amino acid insert in the activation loop that may function in recognition of the unusual amino-terminal phosphorylation site on cofilin. Alternatively, the basic residues may provide the substrate determinants for Thr508 analogous to those of other substrates for kinases such as cAMP-dependent protein kinase and protein kinase C (53, 54). To investigate the function of this insert, 2 mutants were constructed: in one, the kinase insert was deleted (KI-del.) and in the other, the basic residues 502Arg-Lys-Lys were mutated to Gly-Ala-Ala (KI-mut) (Fig. 1). Both mutants failed to induce significant actin aggregation in COS-7 cells (Fig. 10, A-D). Activity was clearly reduced compared with the wild-type enzyme (Fig. 10, E and F) as even high levels of expression of these mutant forms of LIM kinase resulted in no more than 2+ changes in the actin cytoskeleton. No change in subcellular localization was noted by mutation or deletion of the kinase insert region.


View larger version (92K):
[in this window]
[in a new window]
 
Fig. 10.   The basic insert sequence affects the actin aggregating activity of LIM kinase. COS-7 cells were transfected with 1 µg of either kinase insert-deleted LIM kinase (A and B), the 3 amino acid kinase insertion mutation (C and D), or Kd3 containing the kinase insert mutation (E and F). Cells were stained for LIM kinase (left panels) and actin (right panels).

Mutations in LIM kinase Affect Phosphorylation of Cofilin in Vitro-- Immunoisolated LIM kinase-catalyzed phosphorylation of cofilin in vitro. As shown in Fig. 11A, both wild-type and Kd3 LIM kinase catalyzed phosphorylation of cofilin in vitro. LIM kinase catalyzed phosphorylation of myelin basic protein to a low stoichiometry whereas cAMP-dependent protein kinase and protein kinase C efficiently catalyzed phosphorylation of MBP but not cofilin (data not shown).


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 11.   In vitro phosphorylation of cofilin by wild-type and mutant LIM kinase. All DNAs were transfected into HEK 293 cells and lysates were used in in vitro kinase assays and Western blotting as described under "Experimental Procedures." A, left: LIM kinase inactivation by dephosphorylation. Immunoprecipitated LIM kinase and Kd3 were incubated without or with CIP, washed, and in vitro kinase activity assayed using cofilin and [gamma -32P]ATP as substrates. An autoradiogram of 32P-labeled cofilin (upper panel) and a Western blot of immunoprecipitated LIM kinase and Kd3 (lower panel) are shown. A, right: effects of mutations in the amino terminus of LIM kinase on phosphorylation of cofilin. Immunoprecipitated LIM kinase mutants were assayed for in vitro kinase activity (upper panel) and blotted for protein amount (lower panel). B, effects of mutations within the kinase domain on activity. Various forms of LIM kinase were immunoprecipitated and assayed for phosphorylation of cofilin (upper panel). Western blotting was used to adjust the amount of enzyme used in enzyme assays (lower two panels). C, determination of Km for cofilin. The indicated concentrations of cofilin were added to solution assays containing Kd3 and incubated for 12 min at 30 °C. Incorporation of 32P into cofilin was quantitated as described under "Experimental Procedures." D, phosphorylation of Ser3 of cofilin. Lysates of 293 cells transfected with WT LIM kinase were used in kinase assays containing WT and mutant cofilin (serine 3 to alanine, S3A) and WT and mutant actophorin (serine 84 to alanine, S84A). Two µg of substrate were used in each reaction. E, effect of dLIM kinase on LIM kinase activity. Reactions contained soluble WT LIM kinase alone or with a 5-fold molar excess of GST dLIM kinase or GST.

To assess the effects of phosphorylation of LIM kinase on kinase activity, immunoprecipitates of wild-type and Kd3 LIM kinase were treated with CIP to remove any phosphate groups and cofilin phosphorylation was measured. As shown in Fig. 11A, CIP treatment abolished the activity of both forms of LIM kinase. Mutation of Thr508 to either Val or Glu markedly reduced kinase activity in vitro in agreement with loss of the effects of these enzymes on the actin cytoskeleton in vivo (Fig. 11B and Table I). However, substitution of 2 Glu residues for the single Thr (Kd3-T508EE) yielded a fully active enzyme (Fig. 11B and Table I). Enzyme activity in vitro thus paralleled effects in vivo indicating that Thr508 is a phosphorylation site that is essential for LIM kinase activity.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Cofilin phosphorylation by various forms of soluble LIM kinase
Cytosols containing the indicated forms of LIM kinase expressed in HEK 293 cells were incubated with 20 µM cofilin in kinase reaction mixtures for 6 min at 30 °C and 32P incorporation into cofilin was measured as described under "Experimental Procedures." Activities were corrected for the amount of enzyme used based on quantitation via Western blotting.

Mutations in the LIM and PDZ domains did not change the ability of LIM kinase to catalyze cofilin phosphorylation in vitro (Fig. 11A and Table I). Similarly, mutations in the kinase insert retained significant activity (Fig. 11B). In more quantitative solution assays of LIM kinase-catalyzed cofilin phosphorylation the kinase insert mutant was also equal to that of the WT enzyme (Table I). All forms of LIM kinase that phosphorylated cofilin to detectable levels also exhibited self-phosphorylation (Fig. 11B). These results suggest that in vitro kinase assays reflect the basal activity of LIM kinase. In the absence of the kinase insert LIM kinase cannot be activated in vivo, resulting in the observed marked reduction in actin aggregation compared with WT LIM kinase. The insert in the activation loop along with Thr508 is thus necessary for full in vivo activity. The Km of LIM kinase for cofilin is 7.6 µM compatible with the intracellular concentration of cofilin (Fig. 11C).

To demonstrate that the phosphorylation seen in vitro is due to LIM kinase phosphorylation of cofilin at serine 3, a series of cofilin mutants were assessed. Fig. 11D shows that wild-type cofilin, actophorin, and actophorin mutated at serine 84, but not cofilin mutated at serine 3, were phosphorylated by LIM kinase in vitro. This demonstrates that LIM kinase specifically phosphorylates serine 3, in agreement with previously published data (9, 10). Under saturating conditions 1 mol of phosphate was incorporated per mol of cofilin. To demonstrate that the amino terminus of LIM kinase specifically inhibits the kinase activity of LIM kinase, purified Kd3 LIM kinase was incubated without or with a GST fusion to the dLIM kinase and in vitro kinase activity measured. As seen in Fig. 11E, GST-dLIM kinase but not GST inhibited LIM kinase catalyzed cofilin phosphorylation.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The actin cytoskeleton is a dynamic structure in which the rates of polymerization and depolymerization of actin control cell motility, cell division, and the formation of specialized structures. The actin-binding protein, cofilin, is an important regulator of this process, mediating cleavage and disassembly of actin filaments (14). Phosphorylation of cofilin at Ser3 in the amino terminus inactivates the actin cleaving/depolymerizing activity of this protein (55). Phosphorylation and dephosphorylation of cofilin thus provides an important control point for dynamic changes in the extent of actin polymerization and consequent function. Arber et al. (9) and Yang et al. (10) provided evidence that LIM kinase phosphorylates and inactivates cofilin. In co-transfection and microinjection experiments LIM kinase blocked the effects of cofilin, but not those of a mutant cofilin containing an Ala replacement of the Ser3 phosphorylation site. A kinase-inactive form of LIM kinase lacked activity but blocked the effects of LIM kinase. Importantly, both Arber et al. (9) and Yang et al. (10) reported that the LIM kinase mediated phosphorylation of cofilin and resultant cytoskeletal changes were enhanced by the constitutively active V12 mutant of Rac and reduced by the dominant negative N17 mutant of Rac. These findings support a model in which Rac activates LIM kinase which phosphorylates and inactivates cofilin resulting in decreased rates of actin depolymerization. The mechanisms through which Rac regulates LIM kinase activity are unknown but do not involve direct interactions between these two proteins (10).

The present studies confirm cofilin phosphorylation by LIM kinase and demonstrate that in vivo LIM kinase causes changes in actin cables with progressive accumulation of large aggregates of actin consistent with loss of cofilin function. This biological "read out" was used to assess the contribution of various regions of LIM kinase to activity and to compare these results to cofilin phosphorylation in vitro.

While the structure of LIM kinase is unique in having 2 amino-terminal LIM domains and a PDZ domain, it resembles other kinases such as Src whose activity is regulated by modular protein domains located outside the catalytic kinase core (56, 57). Both LIM and PDZ domains function in protein-protein interactions as do the SH2 and SH3 domains in Src (58-60). While the LIM and PDZ domains of LIM kinase likely recognize proteins important in the overall biological function of this protein, the present data indicate these domains also regulate the kinase activity of LIM kinase. Mutation of LIM1 had no detectable effect on LIM kinase activity but mutational inactivation of the second LIM domain and of the PDZ domain enhanced biological activity of LIM kinase in vivo, suggesting these domains directly or indirectly restrict activity. The observation that a kinase-only construct Kd3 also exhibited enhanced biological activity supported this idea. The kinase-inactive D460N LIM kinase acted in a dominant interfering manner consistent with in vitro studies showing self-association (44). The finding that a naturally occurring splice variant of LIM kinase that consists of the amino terminus only (LIM plus PDZ domains) inhibited not only the wild-type but also the kinase domain-only Kd3 mutant suggests that the self-association between the amino- and carboxyl-terminal portions observed in vitro also occurs in vivo. These data support a model of LIM kinase in which the amino terminus interacts with the kinase domain to suppress activity. In addition to the splice variant identified in this article, one LIM kinase-1 and four LIM kinase 2 splice variants have been identified (2, 6, 43). Three of these variants contain deletions that disrupt the kinase domain while one contains only a kinase domain and is expressed only in testis. The ability of dLIM kinase to inhibit Kd3 suggests that these kinase inactive splice variants may, depending on levels of expression, function as naturally occurring inhibitors of LIM kinase.

Several motifs within the kinase domain appear to control kinase activity. The kinase domain contains both Thr and Tyr residues in the activation loop as well as a distinct basic 11-amino acid insertion. The present data indicate that Thr508 is an essential phosphorylation site but Tyr507 is not. A Val substitution at residue 508 abolished actin aggregating activity and a negatively charged Glu that was predicted to partially mimic phosphorylated Thr similarly resulted in loss of activity. However, placement of 2 Glu residues in this position resulted in a fully active enzyme both in vivo and in vitro. Phosphorylation of Thr in the activation loop of several Ser/Thr kinases is essential for catalytic activity (61). In the MAPK signal transduction pathway, both MAPK kinase (Mek) and MAPK are regulated by dual phosphorylations in the activation loop. Mek1 is activated by phosphorylation of 2 nearby Ser residues and replacement of both with Asp is necessary for full activity (51). Mek activation of MAPK requires phosphorylation of both a Tyr and Thr residue in the activation loop (49). However, A kinase and CDK are phosphorylated on a single Thr residue in this loop (45, 46). While additional phosphorylations may regulate LIM kinase, that of Thr508 is essential. The requirement for 2 Glu residues for activity may be due to interactions with the adjacent basic insertion region. Because bacterially expressed LIM kinase did not exhibit self-phosphorylation on Thr (and had very low catalytic activity) (6) phosphorylation of Thr508 is predicted to occur in trans. The sequence of the Thr508 site in LIM kinase, 504Lys-Lys-Arg-Tyr-Thr-Val-Val, clearly differs from the phosphorylation site in cofilin (2, 11) making autophosphorylation unlikely. LIM kinase contains the determinants in the active site that are characteristic of protein kinases which are activated by phosphorylation (61). Thus, upstream signals may be transmitted to LIM kinase both via the amino-terminal LIM and PDZ domains and via regulation of a kinase that phosphorylates LIM kinase at Thr508 to activate the enzyme. Protein kinases that are regulated by Rac (for review, see Ref. 62) are candidates to be involved in the signal transduction pathway linking Rac to LIM kinase activation and consequent cytoskeleton changes.

The basic insert in the activation loop which precedes Thr508 likely provides important substrate determinants for phosphorylation at this site. Deletion or mutation of basic residues in this insertion largely abolished LIM kinase activity in vivo. However, the KI deletion did not decrease LIM kinase-catalyzed phosphorylation of cofilin in vitro. These results suggest that while the insert is not required for basal LIM kinase activity, it is necessary for activation of the enzyme in vivo.

LIM kinase thus contains a number of regulatory features consistent with a pivotal role in control of dynamics of the actin cytoskeleton. Relief of inhibitory constraints imposed by amino-terminal LIM and PDZ regulatory domains and phosphorylation of an activation loop Thr are consistent with the general structural features that regulate the activity of other protein kinases and are proposed to be the targets for receipt of upstream signaling information.

    ACKNOWLEDGEMENT

We thank Laurent Blanchoin for cofilin and helpful discussion.

    FOOTNOTES

* This work was supported by National Institutes of Health Grant DK13149.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF134379.

To whom correspondence should be addressed: University of California San Diego, School of Medicine, 9500 Gilman Dr. 0650, La Jolla, CA 92093-0650. Tel.: 619-534-4310; Fax: 619-534-8193; E-mail: ggill{at}ucsd.edu.

2 P. M. Guy, D. A. Kenny, and G. N. Gill, submitted for publication.

    ABBREVIATIONS

The abbreviations used are: PCR, polymerase chain reaction; nt, nucleotide; RT-PCR, reverse transcriptase-PCR; LIM1, LIM domain 1; LIM2, LIM domain 2; CIP, calf intestinal alkaline phosphatase; GST, glutathione S-transferase; MAPK, mitogen-activated protein kinase.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
  1. Pawson, T. (1995) Nature 373, 573-580[CrossRef][Medline] [Order article via Infotrieve]
  2. Bernard, O., Ganiatsas, S., Kannourakis, G., and Dringen, R. (1994) Cell Growth Differ. 5, 1159-1171[Abstract]
  3. Mizuno, K., Okano, I., Ohashi, K., Nunoue, K., Kuma, K., Miyata, T., and Nakamura, T. (1994) Oncogene 9, 1605-1612[Medline] [Order article via Infotrieve]
  4. Okano, I., Hiraoka, J., Otera, H., Nunoue, K., Ohashi, K., Iwashita, S., Hirai, M., and Mizuno, K. (1995) J. Biol. Chem. 270, 31321-31330[Abstract/Free Full Text]
  5. Cheng, A. K., and Robertson, E. J. (1995) Mech. Dev. 52, 187-197[CrossRef][Medline] [Order article via Infotrieve]
  6. Proschel, C., Blouin, M. J., Gutowski, N. J., Ludwig, R., and Noble, M. (1995) Oncogene 11, 1271-1281[Medline] [Order article via Infotrieve]
  7. Mori, T., Okano, I., Mizuno, K., Tohyama, M., and Wanaka, A. (1997) Brain Res. Mol. Brain Res. 45, 247-254[CrossRef][Medline] [Order article via Infotrieve]
  8. Frangiskakis, J. M., Ewart, A. K., Morris, C. A., Mervis, C. B., Bertrand, J., Robinson, B. F., Klein, B. P., Ensing, G. J., Everett, L. A., Green, E. D., Proschel, C., Gutowski, N. J., Noble, M., Atkinson, D. L., Odelberg, S. J., and Keating, M. T. (1996) Cell 86, 59-69[Medline] [Order article via Infotrieve]
  9. Arber, S., Barbayannis, F., Hanser, H., Schneider, C., Stanyon, C., Bernard, O., and Caroni, P. (1998) Nature 393, 805-809[CrossRef][Medline] [Order article via Infotrieve]
  10. Yang, N., Higuchi, O., Ohashi, K., Nagata, K., Wada, A., Kangawa, K., Nishida, E., and Mizuno, K. (1998) Nature 393, 809-812[CrossRef][Medline] [Order article via Infotrieve]
  11. Yonezawa, N., Nishida, E., Ohba, M., Seki, M., Kumagai, H., and Sakai, H. (1989) Eur. J. Biochem. 183, 235-238[Abstract]
  12. Adams, M. E., Minamide, L. S., Duester, G., and Bamburg, J. R. (1990) Biochemistry 29, 7414-7420[Medline] [Order article via Infotrieve]
  13. Hayden, S. M., Miller, P. S., Brauweiler, A., and Bamburg, J. R. (1993) Biochemistry 32, 9994-10004[Medline] [Order article via Infotrieve]
  14. Theriot, J. A. (1997) J. Cell Biol. 136, 1165-1168[Free Full Text]
  15. Carlier, M. F., Laurent, V., Santolini, J., Melki, R., Didry, D., Xia, G. X., Hong, Y., Chua, N. H., and Pantaloni, D. (1997) J. Cell Biol. 136, 1307-1322[Abstract/Free Full Text]
  16. Hawkins, M., Pope, B., Maciver, S. K., and Weeds, A. G. (1993) Biochemistry 32, 9985-9993[Medline] [Order article via Infotrieve]
  17. Yonezawa, N., Nishida, E., and Sakai, H. (1985) J. Biol. Chem. 260, 14410-14412[Abstract/Free Full Text]
  18. Gunsalus, K. C., Bonaccorsi, S., Williams, E., Verni, F., Gatti, M., and Goldberg, M. L. (1995) J. Cell Biol. 131, 1243-1259[Abstract]
  19. Abe, H., Obinata, T., Minamide, L. S., and Bamburg, J. R. (1996) J. Cell Biol. 132, 871-885[Abstract]
  20. Lappalainen, P., and Drubin, D. G. (1997) Nature 388, 78-82[CrossRef][Medline] [Order article via Infotrieve]
  21. Morgan, T. E., Lockerbie, R. O., Minamide, L. S., Browning, M. D., and Bamburg, J. R. (1993) J. Cell Biol. 122, 623-633[Abstract]
  22. Moriyama, K., Iida, K., and Yahara, I. (1996) Genes Cells 1, 73-86[Abstract/Free Full Text]
  23. Hanks, S. K., and Quinn, A. M. (1991) Methods Enzymol. 200, 38-62[Medline] [Order article via Infotrieve]
  24. Dawid, I. B., Toyama, R., and Taira, M. (1995) C. R. Acad. Sci. Paris Ser. III 318, 295-306[Medline] [Order article via Infotrieve]
  25. Jurata, L. W., Kenny, D. A., and Gill, G. N. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 11693-11698[Abstract/Free Full Text]
  26. Turner, C. E., and Miller, J. T. (1994) J. Cell Sci. 107, 1583-1591[Abstract/Free Full Text]
  27. Sadler, I., Crawford, A. W., Michelsen, J. W., and Beckerle, M. C. (1992) J. Cell Biol. 119, 1573-1587[Abstract]
  28. Xia, H., Winokur, S. T., Kuo, W. L., Altherr, M. R., and Bredt, D. S. (1997) J. Cell Biol. 139, 507-515[Abstract/Free Full Text]
  29. Pomies, P., Louis, H. A., and Beckerle, M. C. (1997) J. Cell Biol. 139, 157-168[Abstract/Free Full Text]
  30. Arber, S., Hunter, J. J., Ross, J., Jr., Hongo, M., Sansig, G., Borg, J., Perriard, J. C., Chien, K. R., and Caroni, P. (1997) Cell 88, 393-403[Medline] [Order article via Infotrieve]
  31. Songyang, Z., Fanning, A. S., Fu, C., Xu, J., Marfatia, S. M., Chishti, A. H., Crompton, A., Chan, A. C., Anderson, J. M., and Cantley, L. C. (1997) Science 275, 73-77[Abstract/Free Full Text]
  32. Mandai, K., Nakanishi, H., Satoh, A., Obaishi, H., Wada, M., Nishioka, H., Itoh, M., Mizoguchi, A., Aoki, T., Fujimoto, T., Matsuda, Y., Tsukita, S., and Takai, Y. (1997) J. Cell Biol. 139, 517-528[Abstract/Free Full Text]
  33. Nakanishi, H., Obaishi, H., Satoh, A., Wada, M., Mandai, K., Satoh, K., Nishioka, H., Matsuura, Y., Mizoguchi, A., and Takai, Y. (1997) J. Cell Biol. 139, 951-961[Abstract/Free Full Text]
  34. Horton, R. M., Hildebrand, W. H., Martinko, J. M., and Pease, L. R. (1990) J. Immunol. 145, 1782-1787[Abstract/Free Full Text]
  35. Ho, S. N., Hunt, H. D., Horton, R. M., Pullen, J. K., and Pease, L. R. (1989) Gene (Amst.) 77, 51-59[CrossRef][Medline] [Order article via Infotrieve]
  36. Wu, R., Durick, K., Songyang, Z., Cantley, L. C., Taylor, S. S., and Gill, G. N. (1996) J. Biol. Chem. 271, 15934-15941[Abstract/Free Full Text]
  37. Chen, C., and Okayama, H. (1987) Mol. Cell. Biol. 7, 2745-2752[Medline] [Order article via Infotrieve]
  38. Kagen, A., and Glick, M. (1979) in Methods of Hormone Radioimmunoassay (Jaffe, B. B., and Behrman, H. R., eds), pp. 328-329, Academic Press, New York
  39. Perez-Alvarado, G. C., Miles, C., Michelsen, J. W., Louis, H. A., Winge, D. R., Beckerle, M. C., and Summers, M. F. (1994) Nat. Struct. Biol. 1, 388-398[Medline] [Order article via Infotrieve]
  40. Kosa, J. L., Michelsen, J. W., Louis, H. A., Olsen, J. I., Davis, D. R., Beckerle, M. C., and Winge, D. R. (1994) Biochemistry 33, 468-477[Medline] [Order article via Infotrieve]
  41. Doyle, D. A., Lee, A., Lewis, J., Kim, E., Sheng, M., and MacKinnon, R. (1996) Cell 85, 1067-1076[Medline] [Order article via Infotrieve]
  42. Herberg, F. W., Zimmermann, B., McGlone, M., and Taylor, S. S. (1997) Protein Sci. 6, 569-579[Abstract/Free Full Text]
  43. Ikebe, C., Ohashi, K., and Mizuno, K. (1998) Biochem. Biophys. Res. Commun. 246, 307-312[CrossRef][Medline] [Order article via Infotrieve]
  44. Hiraoka, J., Okano, I., Higuchi, O., Yang, N., and Mizuno, K. (1996) FEBS Lett. 399, 117-121[CrossRef][Medline] [Order article via Infotrieve]
  45. Morgan, D. O. (1995) Nature 374, 131-134[CrossRef][Medline] [Order article via Infotrieve]
  46. Adams, J. A., McGlone, M. L., Gibson, R., and Taylor, S. S. (1995) Biochemistry 34, 2447-2454[Medline] [Order article via Infotrieve]
  47. Johnson, L. N., and O'Reilly, M. (1996) Curr. Opin. Struct. Biol. 6, 762-769[CrossRef][Medline] [Order article via Infotrieve]
  48. Ben-David, Y., Letwin, K., Tannock, L., Bernstein, A., and Pawson, T. (1991) EMBO J. 10, 317-325[Abstract]
  49. Robbins, D. J., Zhen, E., Owaki, H., Vanderbilt, C. A., Ebert, D., Geppert, T. D., and Cobb, M. H. (1993) J. Biol. Chem. 268, 5097-5106[Abstract/Free Full Text]
  50. Orr, J. W., and Newton, A. C. (1994) J. Biol. Chem. 269, 27715-27718[Abstract/Free Full Text]
  51. Huang, W., Kessler, D. S., and Erikson, R. L. (1995) Mol. Biol. Cell 6, 237-245[Abstract]
  52. Jiang, Y., Li, Z., Schwarz, E. M., Lin, A., Guan, K., Ulevitch, R. J., and Han, J. (1997) J. Biol. Chem. 272, 11096-11102[Abstract/Free Full Text]
  53. Nishikawa, K., Toker, A., Johannes, F. J., Songyang, Z., and Cantley, L. C. (1997) J. Biol. Chem. 272, 952-960[Abstract/Free Full Text]
  54. Songyang, Z., Blechner, S., Hoagland, N., Hoekstra, M. F., Piwnica-Worms, H., and Cantley, L. C. (1994) Curr. Biol. 4, 973-982[Medline] [Order article via Infotrieve]
  55. Agnew, B. J., Minamide, L. S., and Bamburg, J. R. (1995) J. Biol. Chem. 270, 17582-17587[Abstract/Free Full Text]
  56. Xu, W., Harrison, S. C., and Eck, M. J. (1997) Nature 385, 595-602[CrossRef][Medline] [Order article via Infotrieve]
  57. Sicheri, F., Moarefi, I., and Kuriyan, J. (1997) Nature 385, 602-609[CrossRef][Medline] [Order article via Infotrieve]
  58. Cooper, J. A., Gould, K. L., Cartwright, C. A., and Hunter, T. (1986) Science 231, 1431-1434[Medline] [Order article via Infotrieve]
  59. Liu, X., Brodeur, S. R., Gish, G., Songyang, Z., Cantley, L. C., Laudano, A. P., and Pawson, T. (1993) Oncogene 8, 1119-1126[Medline] [Order article via Infotrieve]
  60. Jurata, L. W., and Gill, G. N. (1998) Curr. Top. Microbiol. Immunol. 228, 75-113[Medline] [Order article via Infotrieve]
  61. Johnson, L. N., Noble, M. E., and Owen, D. J. (1996) Cell 85, 149-158[Medline] [Order article via Infotrieve]
  62. Hall, A. (1998) Science 279, 509-514[Abstract/Free Full Text]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.